Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Deal Watch: More Predictions 2017 Will Be A Banner Year For Deal-Making

Executive Summary

PwC anticipates a streamlining of the FDA approval process could address asset scarcity. AbbVie begins 2017 with three modest-sized deals, while PharmAthene and Altimmune join forces in a reverse-merger.

Advertisement

Related Content

J&J's Actelion Courtship Seen Unaffected By Macitentan MAESTRO Failure
Takeda Targets Severe Epilepsies In Ovid Alliance
Lilly Pays Nearly $1bn To Regain Migraine Candidate It Once Sold For $1m
Biogen Pays $1.25bn For Peace Of Mind Over Tecfidera, But Legal Wrangling Continues
AbbVie Picks Up Dong-A Candidate As It Makes Immuno-Onc Inroads
Pharma Is Ready And Waiting For A Tax Holiday Under Trump

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register